News

Patented Medicine Prices Review Board issues a Notice of Hearing for allegations of excessive pricing of Procysbi

January 16, 2019

The Patented Medicine Prices Review Board will hold a public hearing in the matter of the price of the patented medicine cysteamine bitartrate, sold under the trade name “Procysbi” by the patentee Horizon Therapeutics Canada.


Canadian per capita use and spending on drugs for chronic retinal diseases among the highest in the OECD

December 12, 2018

Spending on drug class grew by 16.7% in 2017 and stands at just under $700 million


Patented Medicine Prices Review Board seeks applicants for Vice-Chairperson and Board member positions

December 5, 2018

Governor in Council selection processes underway


Public Drug Plan Expenditures Continue to Rise in 2016-17

September 11, 2018

Increased spending on high cost drugs and reduced savings from generics responsible for 6.3% average growth over 2 years.


Federal Minister of Health tables the 2017 Annual Report of the Patented Medicine Prices Review Board

August 22, 2018

The Honourable Ginette Petitpas Taylor, Federal Minister of Health, today tabled the 2017 Annual Report of the Patented Medicine Prices Review Board (PMPRB) with the Clerks of the House of Commons and the Senate.


PAGE 1 - 2 - 3 - 4 - 5  NEXT 25  LAST 5 
Date modified: